Keck School Faculty

Tommy Sheu
Tommy Sheu
Assistant Professor of Clinical Radiation Oncology
Radiation Oncology
1441 Eastlake Avenue Health Sciences Campus Los Angeles
Tommy Sheu, MD, MPH is an Assistant Professor of Clinical Radiation Oncology in the Keck School of Medicine at the University of Southern California. He primarily treats patients at USC's satellite clinic located at the Fred A. Jordan Radiation Oncology Center at St. Jude Medical Center in Fullerton, CA. He joined USC's Department of Radiation Oncology in August 2019.

Dr. Sheu graduated from Pomona College in Claremont, CA with a Bachelor of Arts in Chemistry. He received his medical degree at Baylor College of Medicine and his Master of Public Health at The University of Texas School of Public Health in Houston, TX. After completing his internship in Internal Medicine at the University of Hawaii John A. Burns School of Medicine in Honolulu, Dr. Sheu completed his residency in radiation oncology at The University of Texas MD Anderson Cancer Center in Houston, TX.

Dr. Sheu is interested in patient-centered outcomes research and is interested in designing clinical tools to help guide clinical decisions. He has published research on cancers of the head and neck, lung, central nervous system and lymphoma. His foremost passion is providing the best, individualized care for his patients.

Clinical Expertise: Head and Neck, CNS, Lymphoma

Comparative Effectiveness of Computed Tomography- Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma Value Health. 2019 Mar; 22(3):284-292. . View in PubMed

Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting JAMA Intern Med. 2019 Mar 01; 179(3):324-332. . View in PubMed

Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage? Adv Radiat Oncol. 2019 Jan-Mar; 4(1):50-56.. View in PubMed

Dosimetric advantages of stereotactic radiosurgery as a boost to adjuvant conventional radiotherapy in the setting of adenoid cystic carcinoma of the parotid with skull base invasion Clin Case Rep. 2018 Nov; 6(11):2126-2130. . View in PubMed

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. . View in PubMed

Incompletely treated malignancies of the major salivary gland: Toward evidence-based care Head Neck. 2018 08; 40(8):1630-1638. . View in PubMed

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154. . View in PubMed

Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis Am J Clin Oncol. 2018 Jan; 41(1):46-52. . View in PubMed

Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base Cancer. 2017 05 01; 123(9):1653-1661. . View in PubMed

Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation Int J Cancer. 2016 Mar 01; 138(5):1290-7. . View in PubMed

Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):850-7. . View in PubMed

Nomogram for predicting symptom severity during radiation therapy for head and neck cancer Otolaryngol Head Neck Surg. 2014 Oct; 151(4):619-26. . View in PubMed

Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):570-5. . View in PubMed

Use of the LQ model with large fraction sizes results in underestimation of isoeffect doses Radiother Oncol. 2013 Oct; 109(1):21-5. . View in PubMed

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer Radiat Oncol. 2012 Sep 11; 7:154. . View in PubMed

Powered by SC CTSI
Go to Top